This paper presents the preliminary results of a study designed to evaluate the effects of alpha interferon in chronic hepatitis B. After six months' treatment with interferon alfa-2b (5 million units (MU), three times weekly) 15 of 25 (60%) patients achieved seroconversion of hepatitis B e antigen, 17 (68%) normalised alanine aminotransferase (ALT) activity, and 15 (60%) showed a decrease in the inflammatory reaction on liver histology. No seroconversions occurred in the control group (n=10), and none of the control patients achieved a normal ALT or showed a reduction in the inflammatory reaction. Adverse effects were experienced by most patients who received interferon but none warranted stopping the treatment. (Gut 1993; supplement: S101) A controlled study was undertaken to evaluate the effects of alpha interferon in patients with liver biopsy proved chronic active hepatitis B (HBV). The preliminary results are presented here.
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Adverse effects were experienced by most of the patients who received interferon (including six with hepatitis like illness, 11 with anorexia, 11 with weakness, and 20 with myalgias) but in no case were these serious enough to require stopping treatment.
Conclusions
These preliminary results indicated that six months of treatment with interferon alfa-2b in patients with chronic active hepatitis B achieved seroconversion of HBeAg in 60%, normal serum ALT values in 68%, and reduced inflammatory reaction in 60% of cases, with no serious adverse effects. None of the controls seroconverted or showed any improvements in liver inflammation.
